Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women
WS Dhillo, OB Chaudhri, EL Thompson… - The Journal of …, 2007 - academic.oup.com
WS Dhillo, OB Chaudhri, EL Thompson, KG Murphy, M Patterson, R Ramachandran…
The Journal of Clinical Endocrinology & Metabolism, 2007•academic.oup.comContext: Kisspeptin, the endogenous ligand of the G protein-coupled receptor 54, is a key
regulator of the hypothalamo-pituitary-gonadal (HPG) axis. GPR54-null mice exhibit
reproductive dysfunction, and exogenous kisspeptin potently stimulates the HPG axis in
rodents, primates, and human males. The effects of kisspeptin administration to human
females are unknown. Objective: Our objective was to investigate the effects of kisspeptin on
LH release during the menstrual cycle in female volunteers. Design: Bolus sc kisspeptin-54 …
regulator of the hypothalamo-pituitary-gonadal (HPG) axis. GPR54-null mice exhibit
reproductive dysfunction, and exogenous kisspeptin potently stimulates the HPG axis in
rodents, primates, and human males. The effects of kisspeptin administration to human
females are unknown. Objective: Our objective was to investigate the effects of kisspeptin on
LH release during the menstrual cycle in female volunteers. Design: Bolus sc kisspeptin-54 …
Abstract
Context: Kisspeptin, the endogenous ligand of the G protein-coupled receptor 54, is a key regulator of the hypothalamo-pituitary-gonadal (HPG) axis. GPR54-null mice exhibit reproductive dysfunction, and exogenous kisspeptin potently stimulates the HPG axis in rodents, primates, and human males. The effects of kisspeptin administration to human females are unknown.
Objective: Our objective was to investigate the effects of kisspeptin on LH release during the menstrual cycle in female volunteers.
Design: Bolus sc kisspeptin-54 was administered to female volunteers, and plasma gonadotropins were measured.
Setting: The study took place at a hospital clinical research facility.
Volunteers: Subjects were healthy female volunteers with regular menstrual cycles.
Intervention: 1) Volunteers received a sc bolus injection of kisspeptin-54 (0, 0.2, 0.4, 0.8, 1.6, 3.2, and 6.4 nmol/kg; n = 3–4 per dose) in the follicular phase; and 2) volunteers (n = 8) received a sc bolus injection of either kisspeptin-54 (0.4 nmol/kg) or saline in random order during each phase of the menstrual cycle.
Main Outcome Measures: Plasma gonadotropins were measured.
Results: 1) Kisspeptin-54 caused a dose-dependent increase in mean LH over time at doses from 0.2–6.4 nmol/kg. 2) Kisspeptin-54 increased plasma LH compared with saline injection in all phases of the cycle. The effect of kisspeptin was greatest in the preovulatory phase and least in the follicular phase of the cycle [mean increase in LH over baseline (IU/liter) ± sem for follicular phase was 0.12 ± 0.17; preovulatory phase, 20.64 ± 2.91 (P < 0.001 vs. follicular phase); luteal phase, 2.17 ± 0.79 (P < 0.01 vs. follicular phase)].
Conclusion: Elevation of plasma kisspeptin in human females potently stimulates LH release in the preovulatory phase and provides a novel mechanism for manipulation of the HPG axis in women.
Oxford University Press